Bimzelx

General resource-navigation contact for the medicines listed on the assistance page. Program staff must confirm individual support options. This route does not establish BRIVIACT participation in the current PAP.

Current linked October 2026 form lists these four medicines. CIMZIA has a product-specific exclusion for government-funded healthcare coverage. NAYZILAM prescriptions require an MD or DO signature under the form’s Texas-pharmacy instructions. Submit only requested material; the form prohibits additional or unrequested medical records. Individual eligibility remains subject to program review.

Published online application entry for the current PAP. The page loaded an application shell; authenticated enrollment and submission were not tested.

Page 4 lists the PAP pharmacy phone in the consent-to-receive-communications section. Its demonstrated purpose is questions about program communications; prescription, dispensing and refill routing are not established by this source.

Name the relevant program and authorization or communications request using that form’s instructions. Consolidated because all three reviewed programs publish the same privacy channels. BRIVIACT is not included in this PAP-derived product scope.

Currently linked form is published January 2026. Fax completed enrollment and benefits-verification forms here. Full-service support includes copay/bridge enrollment, specialty-pharmacy routing and prior-authorization or appeal follow-up. Obtain required patient authorization; program support does not replace payer approval.

Current patient page identifies this Nurse Navigator contact for prescription-status and insurance-coverage support. The current form also uses it for communications questions. Navigator support does not provide medical advice.

Officially linked provider enrollment portal. Public retrieval returned an iAssist shell; login and processing were not tested.